U.S. Markets closed

Perrigo Company plc (PRGO)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
75.28+0.63 (+0.84%)
At close: 4:03PM EDT

74.50 -0.78 (-1.04%)
After hours: 6:32PM EDT

People also watch
MYLENDPALXNTEVAREGN
Full screen
Previous Close74.65
Open74.72
Bid74.50 x 400
Ask76.50 x 400
Day's Range74.05 - 75.41
52 Week Range65.47 - 99.14
Volume1,502,678
Avg. Volume1,822,712
Market Cap10.79B
Beta0.64
PE Ratio (TTM)-3.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.64 (0.87%)
Ex-Dividend Date2017-05-24
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journalyesterday

    Health-Care Stocks Get a Boost From Senate Bill Rollout

    Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.

  • Market Realist3 days ago

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent's commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

  • Barrons.com7 days ago

    Valeant: Stop Looking in the Rearview Mirror!

    Shares of specialty pharmaceutical companies, including Valeant Pharmaceuticals International (VRX), Horizon Pharma (HZNP), Perrigo (PRGO), and Mallinckrodt (MNK), have been under pressure for a while now, as investors have remained focused on their business models of raising prices. In offering her upbeat view on specialty-pharmaceutical companies, Chen recommends investors to not "look back, because objects in the rearview mirror can appear closer than they are." In fact, she claims that management has already started to pivot from the old model of constantly rising prices, and the ones that can "innovate and/or save the healthcare system money can thrive under the new order." Chen initiated coverage on Aclaris Therapeutics (ACRS), Horizon Pharma, Impax Laboratories (IPXL), Mallinckrodt, Perrigo, Theravance Biopharma (TBPH), Valeant, Zoetis (ZTS), and Shire (SHPG), which she calls her "highest conviction recommendation.